ECE2022 Poster Presentations Adrenal and Cardiovascular Endocrinology (87 abstracts)
Patients with chronic kidney disease present HPA axis disregulation due to impaired glucocorticoid negative feedback
Laura Boswell 1,2,3 , Miquel Blasco 4 , Luis F. Quintana 4 , Arturo Vega-Beyhart 2 , Judith Viaplana 5 , Gabriela Rodríguez 6 , Daniela Díaz 2 , Carme Vilardell 3 , Mireia Mora 1,2,7,8 , Irene Halperin 1,2,7 , Antonio J. Amor 1 , Gregori Casals 6 & Felicia A. Hanzu 1,2,7,8
1Hospital Clínic de Barcelona, Endocrinology and Nutrition Department, Barcelona, Spain; 2Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 3Althaia, Xarxa Assistencial Universitària de Manresa, Endocrinology and Nutrition Department, Manresa, Spain; 4Hospital Clínic de Barcelona, Nephrology Department, Barcelona, Spain; 5Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain; 6Hospital Clínic de Barcelona, Biochemistry and Molecular Genetics Department, Barcelona, Spain; 7Universitat de Barcelona, Barcelona, Spain; 8Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Carlos III Health Institute, Madrid, Spain
Aims: A few studies have shown disturbances in the hypothalamic-pituitary-adrenal (HPA) axis in chronic-kidney-disease (CKD), of unknown extent and clinical implications. We aimed to study the HPA axis in patients with CKD and its association with kidney impairment and metabolic disturbances.
Methods: Cross-sectional controlled study. Patients with CKD stages I-II (estimated glomerular filtration rate [eGFR] through CKD-EPI equation >60), stage III (eGFR 30-60) and stage IV (eGFR 15-30) CKD with preserved diuresis (n=16, 15 and 15, respectively) were included and paired with 17 healthy controls by age, sex and body mass index (BMI). Exclusion criteria were: active glucocorticoid, immunosuppressive or anti-inflammatory treatment, diabetes mellitus, morbid obesity, drugs interfering with the HPA axis or pseudo-Cushing states. Subjects underwent clinical and analytical assessment of metabolic comorbidities, body composition analysis using DEXA and a thorough evaluation of the HPA axis.
Results: We included 63 subjects (age 53±12years, 52% women, BMI 26±4kg/m2). A stepped increase in hypertension and dyslipidaemia prevalence as well as increasing levels of glucose, triglycerides and 24h-urinary protein excretion were observed with worsening kidney function (P<0.05 for all). Both plasmatic insulin levels (7.3mIU/L in stages I-II, 11.3 in stage III, 11.4 in stage-IV-CKD, 6.3 in controls; P<0.001) and visceral adipose tissue volume measured using DEXA (663 cm3 in stages I-II, 1042 in stage III, 1347 in stage-IV-CKD, 458 in controls; P<0.001) increased with worsening kidney function. A higher ACTH (23 vs. 17pg/ml, P=0.048) and less cortisol supression after 1 mg dexamethasone-suppression-test (DST) (1.2 vs. 0.9μg/dL, P<0.001) were seen in patients with CKD compared to controls. No differences in ACTH were observed according to CKD stage. 24h-urinary-free-cortisol was decreased in stages III-IV compared to CKD stages I-II and controls (P<0.001). Of all, 11 (24%) patients with CKD had a post-DST cortisol >2 mg/dL (2 [14%] in CKD stage III and 9 [60%] in the stage-IV-group); 45% of them persisted with cortisol >2 mg/dL after a low-dose 2-day-DST (2 mg/6h), all with stage IV (P<0.001 for all). No differences were observed in basal cortisol or cortisol-binding-globulin levels. In the whole cohort, cortisol after DST was lineally inversely correlated with eGFR (β -19.8, P<0.001). Cortisol after DST (OR 11.9, 95%CI 1.5-97, P=0.021) and glucose (OR 1.3, 95%CI 1.1-1.5, P=0.003) were independently associated with an eGFR <30 ml/min/m2.
Conclusions: Negative feedback of the HPA axis is impaired in patients with CKD and correlates with disease stage. This should be taken into account when hypercortisolism is suspected and explored in this context.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more